However, a recent study shows that miR-126 confers platinum resistance in epithelial ovarian cancer through the activation of β-catenin/CBP signaling by targeting its negative regulators such as DKK3, AXIN1, BACH1, and NFAT5.[25] Considering platinum resistant relapses account for most of the mortality, these findings may offer an explanation. This evidence concerns the gene BACH1 and ovarian carcinoma.